FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151730005> ?p ?o ?g. }

• W2151730005 endingPage "28" @default.
• W2151730005 startingPage "21" @default.
• W2151730005 abstract "Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival.Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a 1:1 ratio to receive either comprehensive head and neck radiotherapy alone for 6-7 weeks or radiotherapy plus weekly doses of cetuximab: 400 mg/m(2) initial dose, followed by seven weekly doses at 250 mg/m(2). Randomisation was done with an adaptive minimisation technique to balance assignments across stratification factors of Karnofsky performance score, T stage, N stage, and radiation fractionation. The trial was un-blinded. The primary endpoint was locoregional control, with a secondary endpoint of survival. Following discussions with the US Food and Drug Administration, the dataset was locked, except for queries to the sites about overall survival, before our previous report in 2006, so that an independent review could be done. Analyses were done on an intention-to-treat basis. Following completion of treatment, patients underwent physical examination and radiographic imaging every 4 months for 2 years, and then every 6 months thereafter. The trial is registered at www.ClinicalTrials.gov, number NCT00004227.Patients were randomly assigned to receive radiotherapy with (n=211) or without (n=213) cetuximab, and all patients were followed for survival. Updated median overall survival for patients treated with cetuximab and radiotherapy was 49.0 months (95% CI 32.8-69.5) versus 29.3 months (20.6-41.4) in the radiotherapy-alone group (hazard ratio [HR] 0.73, 95% CI 0.56-0.95; p=0.018). 5-year overall survival was 45.6% in the cetuximab-plus-radiotherapy group and 36.4% in the radiotherapy-alone group. Additionally, for the patients treated with cetuximab, overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash (HR 0.49, 0.34-0.72; p=0.002).For patients with LASCCHN, cetuximab plus radiotherapy significantly improves overall survival at 5 years compared with radiotherapy alone, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients. Cetuximab-treated patients with prominent cetuximab-induced rash (grade 2 or above) have better survival than patients with no or grade 1 rash.ImClone Systems, Merck KGaA, and Bristol-Myers Squibb." @default.
• W2151730005 created "2016-06-24" @default.
• W2151730005 creator A5011905014 @default.
• W2151730005 creator A5012285468 @default.
• W2151730005 creator A5013341404 @default.
• W2151730005 creator A5013854802 @default.
• W2151730005 creator A5014133933 @default.
• W2151730005 creator A5015540964 @default.
• W2151730005 creator A5015582820 @default.
• W2151730005 creator A5021551704 @default.
• W2151730005 creator A5059609929 @default.
• W2151730005 creator A5065694446 @default.
• W2151730005 creator A5077979726 @default.
• W2151730005 creator A5080301921 @default.
• W2151730005 creator A5087816082 @default.
• W2151730005 date "2010-01-01" @default.
• W2151730005 modified "2023-10-10" @default.
• W2151730005 title "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival" @default.
• W2151730005 cites W1554880727 @default.
• W2151730005 cites W1994486276 @default.
• W2151730005 cites W1997097206 @default.
• W2151730005 cites W2000366267 @default.
• W2151730005 cites W2005204942 @default.
• W2151730005 cites W2036005555 @default.
• W2151730005 cites W2043945205 @default.
• W2151730005 cites W2044414901 @default.
• W2151730005 cites W2047948095 @default.
• W2151730005 cites W2057404212 @default.
• W2151730005 cites W2066660289 @default.
• W2151730005 cites W2068125497 @default.
• W2151730005 cites W2072608181 @default.
• W2151730005 cites W2075981888 @default.
• W2151730005 cites W2079103172 @default.
• W2151730005 cites W2089257078 @default.
• W2151730005 cites W2090871977 @default.
• W2151730005 cites W2139273553 @default.
• W2151730005 cites W2139554459 @default.
• W2151730005 cites W2146100972 @default.
• W2151730005 cites W2147582324 @default.
• W2151730005 cites W2151415400 @default.
• W2151730005 cites W2155384808 @default.
• W2151730005 cites W2162238867 @default.
• W2151730005 cites W2167531081 @default.
• W2151730005 cites W2171524637 @default.
• W2151730005 cites W2409420104 @default.
• W2151730005 cites W2562414697 @default.
• W2151730005 cites W4385789423 @default.
• W2151730005 doi "https://doi.org/10.1016/s1470-2045(09)70311-0" @default.
• W2151730005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19897418" @default.
• W2151730005 hasPublicationYear "2010" @default.
• W2151730005 type Work @default.
• W2151730005 sameAs 2151730005 @default.
• W2151730005 citedByCount "1675" @default.
• W2151730005 countsByYear W21517300052012 @default.
• W2151730005 countsByYear W21517300052013 @default.
• W2151730005 countsByYear W21517300052014 @default.
• W2151730005 countsByYear W21517300052015 @default.
• W2151730005 countsByYear W21517300052016 @default.
• W2151730005 countsByYear W21517300052017 @default.
• W2151730005 countsByYear W21517300052018 @default.
• W2151730005 countsByYear W21517300052019 @default.
• W2151730005 countsByYear W21517300052020 @default.
• W2151730005 countsByYear W21517300052021 @default.
• W2151730005 countsByYear W21517300052022 @default.
• W2151730005 countsByYear W21517300052023 @default.
• W2151730005 crossrefType "journal-article" @default.
• W2151730005 hasAuthorship W2151730005A5011905014 @default.
• W2151730005 hasAuthorship W2151730005A5012285468 @default.
• W2151730005 hasAuthorship W2151730005A5013341404 @default.
• W2151730005 hasAuthorship W2151730005A5013854802 @default.
• W2151730005 hasAuthorship W2151730005A5014133933 @default.
• W2151730005 hasAuthorship W2151730005A5015540964 @default.
• W2151730005 hasAuthorship W2151730005A5015582820 @default.
• W2151730005 hasAuthorship W2151730005A5021551704 @default.
• W2151730005 hasAuthorship W2151730005A5059609929 @default.
• W2151730005 hasAuthorship W2151730005A5065694446 @default.
• W2151730005 hasAuthorship W2151730005A5077979726 @default.
• W2151730005 hasAuthorship W2151730005A5080301921 @default.
• W2151730005 hasAuthorship W2151730005A5087816082 @default.
• W2151730005 hasConcept C121608353 @default.
• W2151730005 hasConcept C126322002 @default.
• W2151730005 hasConcept C141071460 @default.
• W2151730005 hasConcept C143998085 @default.
• W2151730005 hasConcept C168563851 @default.
• W2151730005 hasConcept C203092338 @default.
• W2151730005 hasConcept C2776530083 @default.
• W2151730005 hasConcept C2776833033 @default.
• W2151730005 hasConcept C2778570526 @default.
• W2151730005 hasConcept C2779998722 @default.
• W2151730005 hasConcept C509974204 @default.
• W2151730005 hasConcept C526805850 @default.
• W2151730005 hasConcept C71924100 @default.
• W2151730005 hasConceptScore W2151730005C121608353 @default.
• W2151730005 hasConceptScore W2151730005C126322002 @default.
• W2151730005 hasConceptScore W2151730005C141071460 @default.
• W2151730005 hasConceptScore W2151730005C143998085 @default.
• W2151730005 hasConceptScore W2151730005C168563851 @default.
• W2151730005 hasConceptScore W2151730005C203092338 @default.

• next